Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 4Phase NA 2Phase 1/2 2Phase 4 1Phase 2/3 1Phase 1 1

Status

Completed 42Terminated 10Recruiting 10Unknown 8Active not recruiting 3Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 19Colorectal Neoplasms 19Recurrence 17Pancreatic Neoplasms 17Multiple Myeloma 15Advanced Solid Tumors 13Prostatic Neoplasms 12Advanced Solid Tumor 12Stomach Neoplasms 10Ovarian Neoplasms 10Leukemia, Myeloid, Acute 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 8Neoplasm Metastasis 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Lymphoma, Large B-Cell, Diffuse 6Head and Neck Neoplasms 6Glioblastoma 6Urinary Bladder Neoplasms 5Solid Tumors 5Solid Tumor 5Lymphoma, B-Cell 5Lung Neoplasms 5Liver Neoplasms 5Glioma 5Endometrial Neoplasms 5

Interventions

Dexamethasone 2pomalidomide 1isatuximab 1daratumumab 1Lenalidomide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Neoplasms, Plasma Cell × Clear all
NCT07600151 2026-05-20

CONQUISTADOR

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Not yet recruiting
220 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Hellenic Society of Hematology

Phase 1/2 Not yet recruiting
48 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡